ZYDUSLIFE Q2 FY27 Results & Earnings Analysis
Sentiment: Good (Confidence: high)
Earnings Summary
Zydus Lifesciences reported strong Q2 FY27 results with consolidated revenue up 29% YoY to ₹79.1 billion and EBITDA margin at 24%. All business segments delivered double-digit growth: India branded formulations +19%, International formulations +33%, US +21%, Consumer wellness +76%. EBITDA at ₹18.9 billion and net profit at ₹9.3 billion. Key developments include Saroglitazar US launch expected March 2027, Keytruda biosimilar BLA accepted for review, and continued specialty transformation with specialty products at 16% of US revenues. Net debt reduced from ₹5900 crores to ₹5200 crores with net debt/EBITDA at 0.62x. Management maintains 24%+ EBITDA margin guidance for FY27 despite increased Saroglitazar investments.
Management Tone
- Prepared Remarks: Great — Prepared remarks highlighted strong performance across all segments including India branded formulations (19% YoY), US business (21% YoY), and consumer wellness (76% YoY). Management expressed confidence in medium-term aspirations and strategic initiatives like Saroglitazar launch. ,,
- Q&A Session: Good — Management provided detailed and direct answers on key topics including Saroglitazar commercialization plans, margin guidance, US business sustainability, and R&D investments. Some questions on future guidance were deferred to later calls, but management was generally forthcoming.
Revenue Growth Drivers
- Volume expansion in US base business and specialty portfolio scale-up
- Strong domestic branded formulations performance with market share gains in multiple therapies
- New product launches including Riociguat (first generic) in US and continued specialty products traction
Growth vs Margin Focus
Management maintains 24%+ EBITDA margin guidance for FY27 while investing in growth initiatives including Saroglitazar commercialization, R&D for differentiated pipeline, and geographical expansion. Confident in maintaining margins despite investments.
About Zydus Lifesciences Limited
Zydus Lifesciences Limited (ZYDUSLIFE) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.